Valiant Laboratories Ltd (VALIANTLAB) Announcements - Latest Exchange Filings with AI Summaries
Latest corporate announcements filed by Valiant Laboratories Ltd on NSE and BSE, with an AI summary of each filing.
Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
Financial Result · 03 Nov 2026, 12:38 am
Audited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026.
Outcome · 03 Nov 2026, 12:31 am
Valiant Laboratories Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026.
Outcome · 03 Nov 2026, 12:29 am
Valiant Laboratories Reports Q2 FY27 Consolidated Net Profit of Rs 41.34 Lakhs Valiant Laboratories reported consolidated revenue from operations of Rs 11,677.32 lakhs for the quarter ended 30th Sep'26, up 152.7% YoY from Rs 4,620.24 lakhs and up 1.3% QoQ. Consolidated net profit reached Rs 41.34 lakhs versus Rs 20.01 lakhs in the year-ago period, though down sharply from Rs 2,110.30 lakhs in the prior quarter. For H1 FY27, consolidated revenue stood at Rs 23,205.83 lakhs with net profit surging to Rs 2,151.64 lakhs from Rs 202.10 lakhs YoY. Diluted EPS for the quarter was Rs 0.08.
Valiant Laboratories Limited has informed the Exchange about Board Meeting to be held on 02-Nov-2026 to inter-alia consider and approve the Audited Financial results of the Company for the Quarterly ended September 2026 .
Intimation · 02 Nov 2026, 5:30 am
To consider and approve the financial results for the period ended September 30, 2026
Intimation · 02 Nov 2026, 5:30 am
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 02/11/2026 ,inter alia, to consider and approve financial results for ....
Intimation · 02 Nov 2026, 5:30 am
Valiant Laboratories Board Meeting Scheduled for 2nd Nov'26 to Consider Q2 Results Valiant Laboratories Limited announced that its Board of Directors will meet on 2nd Nov'26 to consider and approve the standalone and consolidated audited financial results for the quarter and half year ended 30th Sep'26. In accordance with SEBI insider trading regulations, the company's trading window for dealing in its securities, which has been closed since 29th Sep'26, will remain closed until 4th Nov'26.
Scrutinizer''s Report and Voting Results of 5th AGM of Valiant Laboratories Limited.
Annual General Meeting · 29 Sept 2026, 11:16 pm
Scrutinizer''s Report and Voting Results of 5th AGM of Valiant Laboratories Limited.
Annual General Meeting · 29 Sept 2026, 11:15 pm
Proceedings of 5th Annual General Meeting of Valiant Laboratories Limited held through VC/OAVM.
Annual General Meeting · 28 Sept 2026, 11:22 pm
Please find enclosed
Others (Uncategorized) · 17 Sept 2026, 5:47 pm
Valiant Laboratories Approves Equity Stake in AMPYR Renewable to Procure Captive Solar Power Valiant Laboratories approved acquiring up to a 1.01% equity stake and up to 3.60% CCPS in AMPYR Renewable Energy Resources Twelve A Private Limited for a cash consideration of up to ₹70 lakh. The investment enables the company to procure solar power for its Tarapur plant under a group captive open access arrangement, without altering target management control. AMPYR, operational since 27th May'25, reported FY26 turnover of ₹23.26 crore and net worth of ₹9.99 crore as on 31st Mar'26. The transaction will conclude within 12 months.
Please find enclosed
Others (Uncategorized) · 17 Sept 2026, 5:43 pm
Valiant Laboratories Approves Equity Investment in AMPYR Renewable Energy Valiant Laboratories' Board approved an investment of up to ₹70 lakh in cash to acquire up to 1.01% equity and 3.60% CCPS in AMPYR Renewable Energy Resources Twelve A Private Limited. The move facilitates solar power procurement for the company's Tarapur plant under a group captive open access arrangement. The target, a subsidiary of Singapore-based AMPYR India Asset Holdings Two, reported FY25-26 turnover of ₹23.26 crore and net worth of ₹9.99 crore as of 31st Mar'26. The transaction will conclude within 12 months.
Credit Rating issued by India Ratings & Research Private Limited
Others (Uncategorized) · 03 Sept 2026, 11:10 pm
Valiant Laboratories Receives Ind-Ra Credit Rating for INR 560 Million Bank Facilities On 3rd Sep'26, Valiant Laboratories announced that India Ratings and Research (Ind-Ra) assigned an IND BBB/Stable/IND A2 credit rating to its bank loan facilities. The assigned rating covers debt instruments totaling INR 560 million. This stable outlook provides equity markets with clarity on the company's debt-servicing capabilities and near-term borrowing profile.
Letter to Shareholders under Regulation 36(1)(b) of SEBI (LODR) Regulations, 2015
Others (Uncategorized) · 03 Sept 2026, 11:00 pm
Valiant Laboratories Schedules 5th AGM and Releases FY25-26 Annual Report Valiant Laboratories scheduled its 5th AGM for 28th Sep'26 via video conferencing. On 3rd Sep'26, the company dispatched compliance letters to shareholders without registered emails, providing web links to the FY25-26 Annual Report and AGM notice. The annual report is now available for investor review across company and exchange websites. Shareholders are advised to update their KYC and email records with the registrar, MUFG Intime India, or their respective depository participants to ensure receipt of future electronic communications.
Notice of 5th AGM and Annual Report for FY 2025-26
Annual General Meeting · 03 Sept 2026, 10:45 pm
Annual Report for FY 2025-26.
Others (Uncategorized) · 03 Sept 2026, 10:31 pm
Monitoring Agency Report for the quarter ended June 30, 2026
Others (Uncategorized) · 11 Aug 2026, 2:31 am
Valiant Laboratories: Rights Issue Funds Utilized with No Deviation Valiant Laboratories submitted its monitoring agency report for the quarter ended 30 Jun'26, confirming funds from its Jul'25 Rights Issue were utilized per the offer document with no deviations. The INR 8,146.88 Lakhs issue was fully utilized. A capital expenditure project saw an 84-day delay due to a planned plant shutdown for HVAC installation, now complete. This delay is permitted by the offer document and does not change the issue's objectives. Savings from issue expenses were reallocated to general corporate purposes as allowed.
Opening of a new Corporate Office of the Company
Others (Uncategorized) · 11 Aug 2026, 2:28 am
Valiant Labs Board Approves ₹60 Cr Investment in Subsidiary and Key Appointments Valiant Laboratories' board on 10 Aug'26 approved an additional investment up to ₹60 crore in its wholly-owned subsidiary, Valiant Advanced Sciences (VASPL), via preference shares. The funds will support working capital and corporate purposes for VASPL, a specialty chemicals manufacturer. The board also approved the re-appointment of Santosh Vora as MD and Sonal Vira as Independent Director for five-year terms, both effective from Feb'27. Additionally, the company will shift its registered office to Tarapur, Palghar and open a new corporate office in Vikhroli, Mumbai.
Change in the Registered Office address of the Company, subject to the approval of shareholders and other Statutory Authorities.
Others (Uncategorized) · 11 Aug 2026, 2:26 am
Valiant Labs Board Approves Key Appointments and ₹60 Crore Subsidiary Investment The Board of Valiant Laboratories on 10 Aug'26 approved a ₹60 crore investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), via 1% Optionally Convertible Redeemable Preference Shares. This funding supports VASPL's working capital needs. The board also approved the re-appointment of Mr. Santosh Vora as Managing Director for five years from 06 Feb'27 and Mrs. Sonal Vira as Independent Director for a second five-year term from 16 Feb'27. Additionally, the registered office will be shifted to Palghar, Maharashtra.
Investment in Wholly Owned Subsidiary.
Others (Uncategorized) · 11 Aug 2026, 2:22 am
Valiant Laboratories Board Approves Key Appointments and Subsidiary Investment The Board approved investing up to ₹60 Crore in its wholly-owned subsidiary, Valiant Advanced Sciences (VASPL), via preference shares to fund working capital. Key management re-appointments include Santosh Vora as MD for five years from 06 Feb'27 and Sonal Vira as Independent Director for a second five-year term from 16 Feb'27. The Board also approved shifting its registered office to Tarapur, Boisar, and opening a new corporate office in Vikhroli, Mumbai. All appointments are subject to shareholder approval.
Re-appointment of Managing Director, Independent Director and Continuation of Directorship of Non- Executive Director.
Change in Management · 11 Aug 2026, 2:20 am
Valiant Laboratories Board Approves Investment and Key Management Re-appointments Valiant Laboratories' board on 10 Aug'26 approved a ₹60 Cr investment in its wholly-owned subsidiary, Valiant Advanced Sciences Private Limited (VASPL), via 1% Optionally Convertible Redeemable Preference Shares. This will fund working capital and corporate needs. The board also re-appointed Mr. Santosh Vora as MD for five years from 06 Feb'27 and Mrs. Sonal Vira as Independent Director for a second five-year term from 16 Feb'27. Additionally, the company is shifting its registered office to Palghar and opening a new corporate office in Mumbai.
Audited Standalone and Consolidated Financial Results for quarter ended June 30, 2026.
Financial Result · 11 Aug 2026, 1:59 am
Valiant Laboratories Reports Strong Q1FY27 Standalone and Consolidated Performance Valiant Laboratories reported robust Q1FY27 standalone results for the quarter ended 30th Jun'26. Net profit surged to ₹947.88 lakhs from ₹181.56 lakhs YoY and ₹353.28 lakhs QoQ. Revenue from operations increased 43.9% YoY to ₹7,342.11 lakhs. On a consolidated basis, the company posted a net profit of ₹2,110.30 lakhs against ₹182.09 lakhs YoY. Consolidated revenue grew 146.2% YoY to ₹11,528.51 lakhs. Standalone Basic EPS for the quarter stood at ₹1.75, compared to ₹0.42 in the prior year quarter.
Audited Standalone and Consolidated Financial Results for the quarter ended June 30, 2026.
Outcome · 11 Aug 2026, 1:54 am
Valiant Laboratories Ltd - Financial Result for the Quarter ended 30th Jun'26 (Consolidated, INR Lakh) ■ Revenue: 11,529 (+146.2% YoY | +25.3% QoQ) ■ EBITDA: 2,926 (+1119.5% YoY | +507.8% QoQ) ■ EBITDA Margin (%): 25.4 (+2025 bps YoY | +2015 bps QoQ) ■ PAT: 2,110 (+1058.9% YoY | +1099.9% QoQ) ■ EPS (INR): 3.89 (+826.2% YoY | +1011.4% QoQ)
Valiant Laboratories Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 10/08/2026 ,inter alia, to consider and approve financial results for ....
Intimation · 10 Aug 2026, 5:30 am
Valiant Laboratories Board Meeting on Aug 10, 2026 for Q1FY27 Results Valiant Laboratories has scheduled a Board of Directors meeting on 10th Aug'26 to consider and approve the standalone and consolidated audited financial results for the quarter ending 30th Jun'26. The trading window for insiders has been closed since 26th Jun'26 and will reopen on 12th Aug'26, post the results announcement.
Please find enclosed
Others (Uncategorized) · 30 May 2026, 9:57 pm
Valiant Labs Receives GST Order; Major Allegations Dropped Valiant Laboratories received an order on 29th May'26 from the CGST department confirming a GST demand of Rs. 18 lakhs, plus a penalty of Rs. 18 lakhs and applicable interest. This stems from a Show Cause Notice dated 14th Jan'26, which had initially demanded Rs. 36 lakhs. Significantly, the adjudicating authority dropped other major allegations, including ineligible Input Tax Credit on IPO expenses of Rs. 2.85 crore and a turnover mismatch of Rs. 9.31 crore. The company is evaluating its options, including filing an appeal.
The Exchange has received the disclosure under Regulation 10(5) in respect of acquisition under Regulation 10(1)(a) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, ....
Others (Uncategorized) · 20 May 2026, 3:43 pm
Valiant Organics to Acquire 34.26% Stake in Valiant Laboratories Valiant Organics Limited, a promoter group entity, disclosed its intent on 19 May'26 to acquire 1,86,07,531 equity shares, representing a 34.26% stake, in Valiant Laboratories Ltd. The acquisition from Dhanvallabh Ventures LLP will be via an off-market transaction as part of a restructuring exercise. Post-transaction, Valiant Organics' holding will be 34.26%, while Dhanvallabh Ventures' stake will reduce from 46.84% to 12.58%. The acquisition price will not be more than 25% above the 60-day VWAP of Rs. 62.71 per share.